Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Noa Argamani, a Hamas captivity survivor, was named in Time's annual list of the 100 most influential people of the year 2025 ...

The list of the 100 most influential people in the world. Among those recognised are artists, politicians, business leaders, ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Vertex Pharmaceuticals Inc. closed 5.66% below its 52-week high of $519.88, which the company reached on November 8th.

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.37% to $477.52 Monday, on what proved to be an all-around dismal trading ...

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of ...

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, ...

ToolGen commences legal action in UK court over Vertex's genome editing therapy, CASGEVY ®Seeks to expand licensing of its proprietary CRISPR RNP technologySEOUL, South Korea, April 21, 2025 /PRNewswi ...

$1,600,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Unmet medical need ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.